BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 15139055)

  • 1. Gemcitabine and oxaliplatin in the treatment of patients with immunotherapy-resistant advanced renal cell carcinoma: final results of a single-institution Phase II study.
    Porta C; Zimatore M; Imarisio I; Natalizi A; Sartore-Bianchi A; Danova M; Riccardi A
    Cancer; 2004 May; 100(10):2132-8. PubMed ID: 15139055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gemcitabine plus oxaliplatin for patients with advanced hepatocellular carcinoma using two different schedules.
    Taïeb J; Bonyhay L; Golli L; Ducreux M; Boleslawski E; Tigaud JM; de Baere T; Mansourbakht T; Delgado MA; Hannoun L; Poynard T; Boige V
    Cancer; 2003 Dec; 98(12):2664-70. PubMed ID: 14669287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
    Mani S; Vogelzang NJ; Bertucci D; Stadler WM; Schilsky RL; Ratain MJ
    Cancer; 2001 Sep; 92(6):1567-76. PubMed ID: 11745236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I-II and pharmacokinetic study of gemcitabine combined with oxaliplatin in patients with advanced non-small-cell lung cancer and ovarian carcinoma.
    Faivre S; Le Chevalier T; Monnerat C; Lokiec F; Novello S; Taieb J; Pautier P; Lhommé C; Ruffié P; Kayitalire L; Armand JP; Raymond E
    Ann Oncol; 2002 Sep; 13(9):1479-89. PubMed ID: 12196375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II trial of weekly intravenous gemcitabine administration with interferon and interleukin-2 immunotherapy for metastatic renal cell cancer.
    Neri B; Doni L; Gemelli MT; Fulignati C; Turrini M; Di Cello V; Dominici A; Maleci M; Mottola A; Ponchietti R; Raugei A; Valsuani G; Cini G
    J Urol; 2002 Sep; 168(3):956-8. PubMed ID: 12187198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I trial of sorafenib plus gemcitabine and capecitabine for patients with advanced renal cell carcinoma: New York Cancer Consortium Trial NCI 6981.
    Tagawa ST; Milowsky MI; Jeske S; Mazumdar M; Kung S; Sung M; Lehrer D; Matulich D; Selzer J; Wright JJ; Nanus DM
    Am J Clin Oncol; 2011 Oct; 34(5):443-8. PubMed ID: 20881475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma.
    Nanus DM; Garino A; Milowsky MI; Larkin M; Dutcher JP
    Cancer; 2004 Oct; 101(7):1545-51. PubMed ID: 15378501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of gemcitabine and oxaliplatin in patients with recurrent ovarian cancer: an Australian and New Zealand Gynaecological Oncology Group study.
    Harnett P; Buck M; Beale P; Goldrick A; Allan S; Fitzharris B; De Souza P; Links M; Kalimi G; Davies T; Stuart-Harris R
    Int J Gynecol Cancer; 2007; 17(2):359-66. PubMed ID: 17362313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study.
    Louvet C; André T; Lledo G; Hammel P; Bleiberg H; Bouleuc C; Gamelin E; Flesch M; Cvitkovic E; de Gramont A
    J Clin Oncol; 2002 Mar; 20(6):1512-8. PubMed ID: 11896099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fixed-dose-rate gemcitabine in combination with oxaliplatin in patients with metastatic pancreatic cancer refractory to standard-dose-rate gemcitabine: a single-institute study.
    Fortune BE; Li X; Kosuri KV; Weatherby LM; Thomas JP; Bekaii-Saab TS
    Oncology; 2009; 76(5):333-7. PubMed ID: 19307739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II clinical trial of capecitabine and gemcitabine chemotherapy in patients with metastatic renal carcinoma.
    Waters JS; Moss C; Pyle L; James M; Hackett S; A'hern R; Gore M; Eisen T
    Br J Cancer; 2004 Nov; 91(10):1763-8. PubMed ID: 15505625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemotherapy with gemcitabine and oxaliplatin in patients with advanced biliary tract cancer: a single-institution experience.
    Manzione L; Romano R; Germano D
    Oncology; 2007; 73(5-6):311-5. PubMed ID: 18493158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802.
    Haas NB; Lin X; Manola J; Pins M; Liu G; McDermott D; Nanus D; Heath E; Wilding G; Dutcher J
    Med Oncol; 2012 Jun; 29(2):761-7. PubMed ID: 21298497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gemcitabine and oxaliplatin combination chemotherapy in advanced biliary tract cancers.
    Verderame F; Russo A; Di Leo R; Badalamenti G; Santangelo D; Cicero G; Valerio MR; Gulotta G; Tomasello G; Gebbia N; Fulfaro F
    Ann Oncol; 2006 Jun; 17 Suppl 7():vii68-72. PubMed ID: 16760298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase ii study of gemcitabine and capecitabine in patients with advanced renal cell cancer: Southwest Oncology Group Study S0312.
    Van Veldhuizen PJ; Hussey M; Lara PN; Mack PC; Gandour-Edwards R; Clark JI; Lange MK; Crawford DE
    Am J Clin Oncol; 2009 Oct; 32(5):453-9. PubMed ID: 19487915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I study of the gemcitabine/oxaliplatin combination in patients with advanced solid tumors: a preliminary report.
    Mavroudis D; Kourousis C; Kakolyris S; Agelaki S; Kalbakis K; Androulakis N; Souglakos J; Vardakis N; Samonis G; Georgoulias V
    Semin Oncol; 2000 Feb; 27(1 Suppl 2):25-30. PubMed ID: 10697033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two-weekly gemcitabine fixed dose rate and oxaliplatin combination chemotherapy for advanced non-small-cell lung cancer.
    Früh M; Gillessen S; Cerny T; Demmer R; D'Addario G
    Lung Cancer; 2008 Dec; 62(3):344-50. PubMed ID: 18485522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of gemcitabine plus UFT as salvage treatment in oxaliplatin, irinotecan and fluoropyrimidine-refractory metastatic colorectal cancer.
    Lee KW; Kim YJ; Lee KH; Han SW; Kim TY; Oh DY; Im SA; Kim TY; Bang YJ; Choi IS; Kim JH
    Cancer Chemother Pharmacol; 2014 Sep; 74(3):447-55. PubMed ID: 24947909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II study of oxaliplatin, pemetrexed, and bevacizumab in previously treated advanced non-small cell lung cancer.
    Heist RS; Fidias P; Huberman M; Ardman B; Sequist LV; Temel JS; Lynch TJ
    J Thorac Oncol; 2008 Oct; 3(10):1153-8. PubMed ID: 18827612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gemcitabine-oxaliplatin (GEMOX) as salvage treatment in pretreated epithelial ovarian cancer patients.
    Vici P; Sergi D; Pizzuti L; Mariani L; Arena MG; Barba M; Maugeri-Saccà M; Vincenzoni C; Vizza E; Corrado G; Paoletti G; Tomao F; Tomao S; Giannarelli D; Di Lauro L
    J Exp Clin Cancer Res; 2013 Aug; 32(1):49. PubMed ID: 23927758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.